The PE Ratio as of September 2024 (TTM) for Oncotelic Therapeutics, Inc. (OTLC) is -1.00

According to Oncotelic Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.00. This represents a change of 56.08% compared to the average of -0.64 of the last 4 quarters.

Oncotelic Therapeutics, Inc. (OTLC) Historical PE Ratio (quarterly & annually)

How has OTLC PE Ratio performed in the past?

The mean historical PE Ratio of Oncotelic Therapeutics, Inc. over the last ten years is -1.42. The current -1.00 PE Ratio has changed 6.95% with respect to the historical average. Over the past ten years (40 quarters), OTLC's PE Ratio was at its highest in in the September 2023 quarter at 26.73. The PE Ratio was at its lowest in in the June 2024 quarter at -14.61.

Oncotelic Therapeutics, Inc. (OTLC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Oncotelic Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Oncotelic Therapeutics, Inc. (OTLC) Average PE Ratio

How has OTLC PE Ratio performed in the past?

The current PE Ratio of Oncotelic Therapeutics, Inc. (OTLC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Oncotelic Therapeutics, Inc. (OTLC) PE Ratio vs. Peers

How is OTLC’s PE Ratio compared to its peers?

Oncotelic Therapeutics, Inc.’s PE Ratio is greater than Ceapro Inc. (-2.90), greater than PhaseBio Pharmaceuticals, Inc. (-15.72), less than Processa Pharmaceuticals, Inc. (-0.41), less than Kaleido Biosciences, Inc. (0), less than Advanced Proteome Therapeutics Corporation (-0.01), greater than Cellectis S.A. (-2.83), greater than ChitogenX Inc. (-1.08), greater than Biotron Limited (-2.17), less than Bioasis Technologies Inc. (0), greater than Nascent Biotech, Inc. (-3.72), greater than ProtoKinetix, Incorporated (-12.37), less than RespireRx Pharmaceuticals Inc. (-0.18), less than Silo Pharma, Inc. (-0.90), greater than VG Life Sciences Inc. (-22.79), less than Rubius Therapeutics, Inc. (0), less than Peak Bio, Inc. (-0.06), less than AlloVir, Inc. (0), less than null (-0.11), less than null (-0.62),

Build a custom stock screener for Oncotelic Therapeutics, Inc. (OTLC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncotelic Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncotelic Therapeutics, Inc. (OTLC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncotelic Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.